CanBas Co

CanBas Co SG&A Expenses

The Selling, General & Administrative Expenses of CanBas Co (4575.T) as of Oct 23, 2026 is 57.00 M JPY. In the previous year, Selling, General & Administrative Expenses was 57.00 M JPY — a change of 0.00% (lower).

SG&A Expenses

57.00 MJPY

YoY

0.00%

Last updated:

Selling, General & Administrative Expenses of CanBas Co is 2025 57.00 M JPY. Selling, General & Administrative Expenses of CanBas Co was 2024 57.00 M JPY. It decreases by 0.00% lower compared to the previous year.

The CanBas Co SG&A Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

SG&A Expenses
Date
SG&A Expenses
Jan 1, 2018
225.98 M JPY
Jan 1, 2019
204.55 M JPY
Jan 1, 2020
234.60 M JPY
Jan 1, 2021
226.38 M JPY
Jan 1, 2022
60.00 M JPY
Jan 1, 2023
294.92 M JPY
Jan 1, 2024
57.00 M JPY
Jan 1, 2025
57.00 M JPY
The CanBas Co SG&A Expenses history
YEARSG&A ExpensesYoY
57.00 MJPY0.00%
57.00 MJPY-80.67%
294.92 MJPY+391.54%
60.00 MJPY-73.50%
226.38 MJPY-3.50%
234.60 MJPY+14.69%
204.55 MJPY-9.48%
225.98 MJPY+270.46%
61.00 MJPY-67.58%
188.18 MJPY+4.78%
179.59 MJPY+199.32%
60.00 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CanBas Co Stock analysis

What does CanBas Co do? CanBas Co., Ltd. generates revenue through pharmaceutical research and development, focusing on basic anticancer drug discovery and early clinical development. The company develops drug discovery concepts, selects candidate compounds, conducts simple animal studies, and analyzes basic data on anticancer drug candidates entering development. It also performs preclinical studies for clinical trial applications and manages the initial phase of clinical trials. The primary buyers of these services are pharmaceutical companies seeking to advance their anticancer drug pipelines through early-stage research and development. CanBas Co., Ltd. operates with a team of 12 full-time employees, specializing in anticancer drug research. The company's services are tailored for pharmaceutical firms requiring expertise in early-stage drug development, particularly in the discovery and preclinical phases. Its focus on basic anticancer drug research and early clinical development positions it as a specialized provider in the pharmaceutical R&D sector. The firm's business model relies on providing comprehensive research services to pharmaceutical companies, including concept development, compound selection, animal studies, and data analysis. These services are critical for pharmaceutical firms to progress anticancer drug candidates from discovery to early clinical stages, ensuring efficient and effective development pathways for new treatments. CanBas Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CanBas Co stock

Selling, General & Administrative Expenses of CanBas Co is 57.00 M JPY in 2025.

Selling, General & Administrative Expenses of CanBas Co changed from 57.00 M JPY to 57.00 M JPY, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Selling, General & Administrative Expenses CanBas Co since 2006 – with annual values, charts, and detailed analysis.

SG&A expenses include all non-production costs such as salaries, marketing, rent, and administrative overhead. They are a key component of operating expenses.

Selling, General & Administrative Expenses's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Selling, General & Administrative Expenses's CanBas Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — CanBas Co

All Key Metrics — CanBas Co